Brendan Duffy, MD
Interventional Cardiology · Canton, OHNPI 1497712699
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,378 of the $7,942 with a category attached, or 80.3%. Medtronic accounts for 86.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $6,732 and has fallen 97.1% since, to $196 in 2025.
Across 75 payments — averaging $105.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abiomed$318
- Cardiva Medical, Inc.$238
- Boston Scientific$236
- Abbott$102
- Harmony Biosciences LLC$33
- plus $150 from 10 others
Across 72 payments — averaging $20,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.4M
- Pfizer$83K
- E.r. Squibb & Sons, L.L.C.$34
What the payments were for
- Consulting fees$80%
- Travel & lodging$6,37880%
- Food & beverage$1,55520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $6,863 |
| Abiomed | 12 | $318 |
| Cardiva Medical, Inc. | 17 | $238 |
| Boston Scientific | 15 | $236 |
| Abbott | 2 | $102 |
| Harmony Biosciences LLC | 1 | $33 |
| Terumo Medical Corporation | 1 | $25 |
| Boehringer Ingelheim | 1 | $18 |
| Amgen | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Cordis US CORP. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Pfizer | 2 | $12 |
| AstraZeneca | 1 | $12 |
| Z-medica, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$122
- SYMPLICITY G3$112
How this compares
$7,942 in reported general payments places this provider in the 60th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $43,251 |
| Repatha SureclickEvolocumab | 19 | $21,845 |
| XareltoRivaroxaban | 18 | $12,666 |
| JardianceEmpagliflozin | 14 | $8,380 |
| Ranolazine ErRanolazine | 68 | $7,017 |
| Metoprolol Succinate | 149 | $1,895 |
| Atorvastatin Calcium | 135 | $1,682 |
| Rosuvastatin Calcium | 91 | $1,596 |
| ClopidogrelClopidogrel Bisulfate | 104 | $1,203 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $854 |
| Losartan Potassium | 110 | $772 |
| Ezetimibe | 51 | $707 |
| Nitroglycerin | 30 | $697 |
| Amlodipine Besylate | 64 | $527 |
| Carvedilol | 68 | $466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $43,25137 claims |
| Boehringer IngelheimJardiance | $18 | $8,38014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Canton
- Muhammad SardarCanton$52K
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.